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Abstract
Background: Glucocorticoids (GCs) play a key role in the treatment of allergy. However, the genome-wide effects of GCs on
gene expression in allergen-challenged CD4
+ T cells have not been described. The aim of this study was to perform a
genome-wide analysis to investigate whether allergen-induced gene expression changes in CD4
+ T cells could be reversed
by GCs.
Methodology/Principal Findings: Gene expression microarray analysis was performed to profile gene expression in diluent-
(D), allergen- (A), and allergen + hydrocortisone- (T) challenged CD4
+ T cells from patients with seasonal allergic rhinitis.
Principal component analysis (PCA) showed good separation of the three groups. To identify the correlation between
changes in gene expression in allergen-challenged CD4
+ T cells before and after GC treatment, we performed orthogonal
partial least squares discriminant analysis (OPLS-DA) followed by Pearson correlation analysis. This revealed that allergen-
induced genes were widely reversed by GC treatment (r=20.77, P,0.0001). We extracted 547 genes reversed by GC
treatment from OPLS-DA models based on their high contribution to the discrimination and found that those genes
belonged to several different inflammatory pathways including TNFR2 Signalling, Interferon Signalling, Glucocorticoid
Receptor Signalling and T Helper Cell Differentiation. The results were supported by gene expression microarray analyses of
two independent materials.
Conclusions/Significance: Allergen-induced gene expression changes in CD4
+ T cells were reversed by treatment with
glucocorticoids. The top allergen-induced genes that reversed by GC treatment belonged to several inflammatory pathways
and genes of known or potential relevance for allergy.
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Introduction
Seasonal allergic rhinitis (SAR) is a common airway disease,
which is caused by inhalant allergens such as birch or grass pollen.
Following nasal exposure to the inhaled allergens, antigen
presenting cells in the nasal mucosa present allergen peptides to
CD4
+ T cells [1]. In allergic patients, this results in activation and
proliferation of allergen-specific T helper type 2 (Th2) cells. These
cells release cytokines including IL-4, IL-5 and IL-13, which in
turn activate B cells, eosinophils and mast cells [2,3,4,5].
Glucocorticoids (GCs) are among the most effective drugs for
controlling the inflammation in allergic rhinitis [6,7]. Studies of
nasal polyps and nasal fluids from patients with SAR show that
GCs change the expression of hundreds of genes and proteins
[8,9]. In nasal mucosa, GCs exert anti-inflammatory effects by
decreasing the number of Th2 cells and the production of Th2
cytokines, such as IL-4, IL-5 and IL-13. Interestingly, GCs also
affect Th1 cells and the production of Th1 cytokines such as IL-2,
IL-12 and IFN-c [10,11]. Moreover, GCs decreased the expres-
sion of IFN-c and IFN-c-induced genes in allergen-challenged
CD4
+ T cells from patients with SAR [12]. While GCs generally
decrease the expression of inflammatory genes, GCs treatment
may also increase the expression of anti-inflammatory genes [8].
However, the effects of GCs on gene expression in different cell
types show considerable variation [13,14,15,16,17]. For example,
GCs induce apoptosis in eosinophils, but have the opposite effect
on neutrophils [18].
CD4
+ T cells play crucial roles in allergic rhinitis. Allergen-
challenged CD4
+ T cells provide an in vitro model for studying the
change in genes expression in CD4
+ T cells in response to allergen
challenge and to GC treatment [19]. Although several individual
genes in CD4
+ T cells from patients with SAR have been shown to
be regulated by allergen challenge and GC treatment [12], the
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CD4
+ T cells with allergen challenge have, to our knowledge, not
yet been described. In this study, we hypothesized that GCs
reverse gene expression changes in allergen-challenged CD4
+ T
cells. To test this hypothesis, we examined gene expression
microarray data from CD4
+ T cells from patients with SAR. The
cells were challenged with either diluent (D), allergen (A) or
allergen + hydrocortisone (T) [12]. The data was analyzed with
multivariate- and pathway analysis [9].
Materials and Methods
Ethics statement
This research has been approved by the regional ethics
committee of the University of Gothenburg and the ethics
committee of the University of Padua. We obtained written
informed consent from all subjects. The written consent was
obtained on a special form with information about the study and
the conditions of the study, according to instructions from the
ethics committee (this form was also approved by the ethics
committee, which considers this of great importance for their
approval).
Subjects
First, samples from twelve patients with SAR outside the pollen
season were analyzed and will be referred to as the training set.
The two independent test data sets consisted of 21 patients and 28
patients with SAR outside the pollen season (these materials will
henceforth be referred to as Test1 and Test2, respectively). The
median (range) age of the training set was 23(20–25) and 3 were
women. For the Test1, the median (range) age was 27 (16–46) and
12 were women. For the Test2, the median (range) age was 32
(15–47) and 10 were women. Exclusion criteria included a history
of perennial symptoms and treatment with local or systemic
corticosteroids or antihistamines for the last 2 months. The
training set and Test2 were recruited from Sahlgrenska University
hospital in Go ¨teborg, Sweden while the Test1 cohorts were
collected at Padua University Hospital, Padua, Italy.
Allergen challenge
In the training set, peripheral blood mononuclear cells (PBMCs)
obtained from 12 patients were challenged with diluent (D),
allergen extracts from grass pollen (ALK Abello’, Hørsholm,
Denmark; 100 ug/mL) (A), or allergen + hydrocortisone (10
27 M,
Sigma-Aldrich, St. Louis, Missouri, USA) (T) for 7 days in RPMI
1640 supplemented with 2 mM L-glutamine (PAA Laboratories,
Linz, Austria), 5% human AB serum (Lonza, Switzerland), 5 mM
b–mercaptoethanol (Sigma-Aldrich, St. Louis, Missouri, USA) and
50 ug/mL gentamicin (Sigma-Aldrich, St. Louis, Missouri, USA).
In the Test1, PBMCs obtained from 21 allergic patients outside
the pollen season were challenged with diluent (Test1 D) or
allergen extracts from grass pollen (Test1 A) for one week. In the
Test2, PBMCs obtained from 28 allergic patients outside the
pollen season were challenged by allergen extracts from birch (one
patient) or grass pollen for one week with (Test2 T) or without
(Test2 A) GC treatment.
Gene expression microarray analysis
CD4
+ T cells were isolated using the CD4 Microbeads (Miltenyi
Biotec, Bergisch-Gladbach, Germany) according to the manufac-
turer’s protocol. The typical purity of sorted CD4
+ T cells was
.90%. Total RNA was extracted using the miRNeasy mini kit
(QIAGEN, Valencia, CA, USA) according to manufacturer’s
instructions. The quantity of RNA was measured with a
NanoDrop ND-1000 UV Spectrophotometer (NanoDrop Tech-
nologies, Wilmington, DE, USA). The RNA quality was examined
in an Agilent 2100 Bioanalyzer using the RNA 6000 Pico kit and
the RNA Integrity Number was calculated in Agilent 2100
Bioanalyzer expert software (Agilent Technologies, Palo Alto, CA,
USA). Gene expression microarrays (Illumina, San Diego, CA,
USA) were performed as previously described for the training and
test cohorts [8,20].
Data analysis
Principal Component Analysis (PCA) was used to examine the
systematic trends within the GEM data. Orthogonal partial least
squaresdiscriminantanalysis(OPLS-DA)wasperformedtoidentify
the correlation between changes in gene expression in allergen-
challengedCD4
+TcellswithorwithoutGCtreatment(seedetailed
methods in Method S1). The SUS-plot that combines the Cor(Tp,
X) profiles from two models where classes were compared to a
common reference (group A) was used to identify the shared and
unique structure between classes (Figure S1). The shared genes
between two models with a |Cor(Tp, X)|$0.5 were extracted for
pathway analysis. Both PCA and OPLS-DA were performed with
SIMCA-P+12.0.1 software (UMETRICS, Umea ˚, Sweden). Hier-
archical clustering analysis was performed with GeneSpring GX
software (Agilent Technologies, Palo Alto, CA, USA). Ingenuity
PathwaysAnalysis(IPA)software(http://www.ingenuity.com/)was
usedtomapgenesontoknowncanonicalandcellularandmolecular
pathways [20]. We employed a Fisher’s exact test to calculate a P
value determining the probability whether the association between
the proteins in the dataset and the canonical pathway can be
explained by chance alone. Pathways with a P value less than 0.05
were considered to be statistically significant. Pearson correlation
analysis was performed using the Statistical Package for the Social
Sciences (SPSS) statistical software for Windows, Version 19.0.
Results
Outline of the study
Briefly, we first analyzed a training set consisting of diluent-,
allergen- or allergen + GC-challenged CD4
+ T cells from the
allergic patients with gene expression microarrays (GEM). The
aims were to determine if a) genes whose expression was changed
by allergen would be reversed by treatment and b) which pathways
those genes belonged to. Finally, we showed that the observed
gene expression changes were supported by analysis of two
independent materials, one of which consisted of allergen- or
diluent- challenged CD4
+ T cells (Test1) and another consisting of
allergen and allergen + GC-treated CD4
+ T cells (Test2).
Principal Component Analysis to obtain an overview of
the effects of allergen and glucocorticoids on gene
expression in CD4+ T cells from patients with seasonal
allergic rhinitis
PBMCs from the training set, namely 12 asymptomatic allergic
patients out of pollen season were challenged with diluent (D),
allergen (A) or allergen + hydrocortisone (T). CD4
+ T cells
extracted from the PBMCs were analyzed with GEM. PCA of the
GEM data was performed to obtain an overview of the effects of
the three conditions on gene expression. The PCA resulted in a
model with 4 cross-validatory components. The total explained X
variation (the gene expression data) was 53% and the predicted X
variation was 36%. The PCA scatter plot with the first two
components showed that the three groups (D, A and T) formed
three distinct clusters. Allergen and diluent challenged cells were
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between D and A (Figure 1). This indicated that GCs tended to
reverse allergen-induced gene expression changes in CD4
+ T cells
from allergic patients.
Identification of allergen-induced gene expression
changes that were reversed by GC treatment
We first performed OPLS-DA to identify the genes that most
separated allergen or diluent challenged groups, A and D. Next,
we repeated the analysis to identify the corresponding genes in
allergen and allergen + GC challenged cells, A and T. OPLS-DA
identifies correlation patterns that discriminate groups and
estimates the relative importance of each included gene expression
value for the discrimination [21,22,23]. OPLS-DA of D and A
provided an OPLS model with one predictive component and
three orthogonal components (Model DvsA) (Figure 2A). This
model was significant based on ANOVA of the cross-validated
residuals (CV-ANOVA) (P,0.001) [24]. The total explained Y
variation was 99.6% and the total predicted Y variation was
81.6%. Of the total explained X variation of 52.8%, 24.7%
predicted the discrimination between the groups D and A.
OPLS-DA of A and T provided an OPLS model with one
predictive component and seven orthogonal components (Model
AvsT) (Figure 2B). The CV-ANOVA showed that the Model
AvsT was significant (P,0.001). The total explained Y variation
was 100% and the total predicted Y variation was 42.2%. Of the
total explained X variation of 64.9%, 8.4% of the genes predicted
the discrimination between A and T.
In order to understand how GC treatment affected allergen-
induced gene expression in CD4
+ T cells, we analyzed the
correlation between the covariance of all genes from the two
models by Pearson correlation analysis. The data illustrated an
inverse correlation (r=20.77, P,0.0001) (Figure 3A). In order
to extract the genes that were most reversed by GCs, we used a
SUS-plot, which combined the Cor(Tp) value of each gene from
the two models (Model DvsA and Model AvsT). The SUS-plot
also showed an inversely shared gene structure between the two
models (r=20.97, P,0.0001) (Figure 3B, Table S1). We
extracted 547 genes that were found to be most reversed by
GCs based on a |Cor(Tp)| $0.5 (Figure 3B, Table S2) [25].
Pathway analysis of allergen-induced genes that were
most reversed by glucocorticoids
We performed pathway analysis of the 547 allergen-induced
genes whose expression was reversed by GC treatment, using the
IPA software. The top pathways enriched for these genes included
TNFR2 Signalling, Interferon Signalling, Differential Regulation of Cytokine
Production in Intestinal Epithelial Cells by IL-17A and IL-17F, Airway
Inflammation in Asthma, Glucocorticoid Receptor Signalling and T Helper
Cell Differentiation (Figure 4). We also investigated the cellular and
molecular function of these genes using IPA. The top five cellular
and molecular pathways included cell death, cellular growth and
proliferation, cellular development, gene expression and cell-to-cell signalling
and interaction (Table 1). These pathways included inflammatory
genes of known importance for allergy, such as CSF2, TNF, IFNG,
GZMA, GZMB, IRF4, STAT1 and IL13, or potential relevance for
allergy such as NR3C1 and IL21R (Table 2). Taken together,
these findings indicated that GC treatment reversed gene
expression changes in a wide variety of pathways and genes in
allergen-challenged CD4
+ T cells.
Analyses of allergen-induced gene expression changes
that were reversed by treatment with glucocorticoids in
independent materials
The observed gene expression changes were supported by
analyses of two independent materials, one material consisted of
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Figure 1. PCA modeling of the gene expression microarray
data from diluent- (D), allergen- (A) or allergen + GC treated (T)
CD4
+ T cells from patients with seasonal allergic rhinitis in the
training set.
doi:10.1371/journal.pone.0039016.g001
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Figure 2. OPLS-DA modeling of diluent- (D), allergen- (A) or allergen + GC treated (T) CD4
+ T cells from patients with seasonal
allergic rhinitis in the training set. A) OPLS of D and A (Model DvsA); B) OPLS of A and T (Model AvsT).
doi:10.1371/journal.pone.0039016.g002
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+ T cells from 21
allergic patients (Test1) while the other one consisted of CD4
+ T
cells challenged with allergen (A), or allergen + GC (T) from 28
allergic patients (Test2). Because of the large number of genes
(n=547) the studies were performed with gene expression
microarrays. PCA and hierarchical clustering showed that the
547 genes clearly separated the two groups (Figure 5).
Figure 3. Comparison between Model DvsA and Model AvsT derived from the training set. A) Comparison of the Cov(Tp) of all genes
between Model DvsA and Model AvsT; B) Comparison of the Cor(Tp) of all genes between Model DvsA and Model AvsT. D, diluent-challenged CD4
+ T
cells; A, allergen-challenged CD4
+ T cells; T, allergen-challenged + GC treated CD4
+ T cells. Cov(Tp), the covariance of the predictive component;
Cor(Tp), the correlation of the predictive component.
doi:10.1371/journal.pone.0039016.g003
Figure 4. Pathway analysis of allergen-induced top 547 genes whose expression was reversed by glucocorticoids. The top 547 genes
with a |Cor(Tp)|$0.5 from the two models were extracted and mapped to Ingenuity pathway analysis. The yellow threshold indicates 95%
confidence.
doi:10.1371/journal.pone.0039016.g004
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microarray data from the two Test sets followed by Pearson
correlation analysis of the covariance of all the genes in the two
OPLS-DA models. These analyses also showed an inverse
correlation (r=20.48, P,0.0001), in consistency with the analyses
of the initial material (Figure S2).
Discussion
GCs have an important role in the treatment of allergy and
other inflammatory disorders. GCs have wide-ranging effects on
different tissues and cell types [26,27,28]. Interestingly, while GCs
mainly decrease the expression of inflammatory genes, they may
also increase the expression of anti-inflammatory genes. It is also of
note that the expression of several inflammatory genes is not
affected [8]. From a clinical perspective, 10–30 % of patients with
different inflammatory diseases do not respond to GC treatment
[27,29]. This suggests the need to determine the genome-wide
effects of GCs on disease-related genes as well as which pathways
those genes belong to. Despite the importance of GCs in treating
allergy, there is limited information on the genome-wide effects of
GCs in cells and tissues from allergic patients. One recent study of
nasal fluids, fluid cells and mucosa showed large and diverse effects
on the mRNA and protein expression levels [20]. A previous
analysis of nasal polyps, which have immunohistochemical
similarities with allergic inflammation, also showed large effects
of GCs that were mainly inhibitory, but also in some cases
enhancing [8].
CD4
+ T cells from patients with SAR provide an in vitro model
for studying genes expression changes in response to allergen
challenge and how these are affected by GCs. In this study, we
examined this model with gene expression microarray-, multivar-
iate and pathway analysis. The reason for using multivariate
analysis was that univariate analysis does not take into account the
relationships between variables and their correlations to the
classification between groups. Compared to univariate analysis,
multivariate analysis allows us to interpret and visualize multiple
variables, such as gene expression microarray data, providing
integrated information with less error and more validity. For
instance, PCA modeling of the GEM data enabled us to find that
the gene expression pattern induced by allergen challenge was
potentially reversed by GC treatment. Using the OPLS-DA, we
further indentified the covariance and correlation of the whole
genes to the classification caused by allergen challenge and GC
treatment. The scatter plot of the covariance of the whole genes
and also the SUS plot allowed us to identify that the expression
pattern of whole genes in allergen-challenged CD4
+ T cells was
systematically reversed by GC treatment. These plots also
permitted us to determine allergen-induced genes that were
reversed by GC treatment.
We found that, in general, allergen-induced genes expression
changes were reversed by GC treatment. The genes that were
most affected by allergen- and reversed by GCs belonged to a wide
variety of inflammatory pathways and cellular functions. Several of
those pathways have known roles in allergy, namely TNFR2
Signalling, Interferon Signalling, Differential Regulation of Cytokine
Production in Intestinal Epithelial Cells by IL-17A and IL-17F, Airway
Inflammation in Asthma, Glucocorticoid Receptor Signalling and T Helper
Cell Differentiation. Previous studies have shown important roles for
several genes in those pathways. For example, IFNG is a master
cytokines of Th1 differentiation, while IRF4 has a key role in Th2
differentiation [30,31]. The soluble IL-2RB is known to reflect T
cell involvement and was found to be increased in patients with
allergic disease but to be reduced by GC treatment [32]. Our
approach may also help to identify novel candidate genes in
allergy. The rationale for this assertion is that a gene, whose
expression is induced by allergen and also reversed by GCs, has an
increased likelihood to be relevant for the disease. Examples of
such genes included nuclear receptor subfamily 3, group C,
(NR3C1), which is also known as the glucocorticoid receptor, from
the Glucocorticoid Receptor Signalling, which can be activated by
glucocorticoids [33]. It has recently been reported that NR2C1
increased in nasal mucosal from patients with allergic rhinitis [34].
IL-21 receptor (IL-21R) from the T helper cell differentiation pathway is
important in the development of Th2 response and has been
demonstrated to be essential for allergic skin inflammation in
humans and mice [35,36]. Similar to our findings, a previous study
gene expression microarray study of CD4+ T cells from patients
allergic to house dust mite and healthy showed a Th2-skewed gene
expression profile in the patients [37].
Limitations of our study include that a large number of genes
are analyzed in a small number of patients. This involves the risk
of spurious findings. This suggests the need for validation studies.
However, the large number of genes affected by allergen and GCs
makes validation with low throughput techniques like QPCR
impractical. Other possible confounding factors could be that
cohorts from two different countries were examined, and that
young men were over-represented in the training set. To our
knowledge the influences of ethnic and racial differences on the
expression of genes relevant for allergy have not been character-
Table 1. Cellular and molecular functions of top 547 genes
whose expression changed by allergen and reversed by GCs.
Name P value Molecules
Cell Death 2.6E-10–2.0E-03 122
Cellular Growth and Proliferation 4.3E-07–1.9E-03 147
Cellular Development 1.3E-06–2.0E-03 101
Gene Expression 3.3E-06–2.1E-03 111
Cell-To-Cell Signaling and Interaction 3.5E-06–1.8E-03 67
doi:10.1371/journal.pone.0039016.t001
Table 2. Genes of known relevance for allergy, whose
expression increased following allergen-challenge and were
reversed by treatment with glucocorticoids.
Gene symbols Model DvsA Model AvsT
Cov(Tp) Cor(Tp) Cov(Tp) Cor(Tp)
CSF2 0.034 0.95 20.027 20.54
TNF 0.018 0.95 20.017 20.63
IFNG 0.022 0.88 20.022 20.55
GZMA 0.023 0.81 20.028 20.56
GZMB 0.030 0.89 20.025 20.50
IRF4 0.025 0.92 20.022 20.52
STAT1 0.022 0.85 20.025 20.71
IL13 0.013 0.87 20.018 20.69
NR3C1 0.009 0.66 20.011 20.53
IL21R 0.016 0.79 20.021 20.60
Cov(Tp), the covariance of the predictive component; Cor(Tp), the correlation of
the predictive component.
doi:10.1371/journal.pone.0039016.t002
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Future studies are therefore warranted to elucidate such influenc-
es. Regarding the effects of gender, previous studies by us and
others have shown that gender may influence gene- and protein
expression changes [38]. In this study, we tested the relevance of
our findings in two independent materials, one which consisted of
allergen- and diluent challenged CD4
+ T cells and another
consisting of allergen- and GC treated CD4
+ T cells. These
analyses showed highly significant correlations with the results
from the first study and thereby supported the general relevance of
our findings. A technical limitation of the present study is that we
used positive sorting of CD4
+ T cells by magnetic-activated cell
sorting (MACS), which results in slightly lower purity than
positively sorted cells by fluorescence-activated cell sorting (FACS).
In conclusion, allergen-induced gene expression changes in
CD4
+ T cells were reversed by treatment with glucocorticoids.
The top allergen-induced genes that reversed by GC treatment
belonged to several inflammatory pathways and genes of known or
potential relevance for allergy.
Supporting Information
Figure S1 Illustration of the SUS-plot. A SUS-plot
combining the Cor(Tp, X) from OPLS-DA model 1 and 2 was
illustrated. X variables in the diagonal A were shared by both
models while X variables in the diagonal B were inversely shared.
X variables in the square C and D were unique in the model 1 and
2, respectively.
(EPS)
Figure S2 Inversely shared gene expression structure
between the two independent materials. The scatter plot
combines the Cov (Tp) of all genes in Model DvsA from the Test1
and Model AvsT from the Test2.
(TIF)
Methods S1 Orthogonal partial least squares discrim-
inant analysis.
(DOC)
Table S1 All genes analyzed in OPLS-DA.
(XLS)
Table S2 Inversely correlated genes with high reliabil-
ity.
(XLS)
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Figure 5. Validation studies of top 547 genes whose expression changed in CD4
+ T cells from allergic patients after allergen-
challenge and were reversed by treatment with glucocorticoids. The CD4
+ T cells from allergic patients were obtained from two
independent materials and analysed with gene expression microarrays. PCA (A and B) and hierarchical clustering analysis (C and D) of Test1 (A and
C) and Test2 (B and D) with the top 547 genes that were changed by allergen challenge and were reversed by GC treatment.
doi:10.1371/journal.pone.0039016.g005
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